Health• Updated
New test shows cancer vaccine boosts survival rates in blood disease
Reported by Rituparna Sen (Section Editor) · The Hindu - Health ·

UPDATE - follow-up to Sellas' cancer vaccine extends survival in blood cancer trial, company says: Sellas Life Sciences announced on Tuesday, November 17, 2026, that its test vaccine helped patients with a form of blood cancer live longer in a late-stage study. The shot, known as galinpepimut-S or GPS, was given to patients suffering from acute myeloid leukaemia, which is a fast-growing cancer affecting the blood and bone marrow. Patients who got the GPS vaccine lived a median of 24 months, while those given the best available treatment lived for 14.7 months. The firm now plans to speak with the U.S. Food and Drug Administration to seek approval for the vaccine. The company's shares were halted in premarket trading following the news.
Context
Acute myeloid leukaemia is a serious disease that starts in the bone marrow and quickly spreads into the blood. Drug companies must complete late-stage trials and talk closely with health regulators like the U.S. FDA before any new medicine can be sold to patients.
What changed since yesterday
- Experimental Cancer Vaccine Extends Survival in Blood Cancer Trial
Latest
New test shows cancer vaccine boosts survival rates in blood disease
More in Health

HealthExplainerSource: The HinduWorth knowing
Experimental Cancer Vaccine Extends Survival in Blood Cancer Trial.
Reported by Faizan Khan (Staff Writer) · The Hindu - Health ·
